Skip to main content
Journal cover image

AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV)

Publication ,  Journal Article
Desjardins, A; Herndon, J; McSherry, F; Ravelo, A; Lipp, E; Healy, P; Peters, K; Vlahovic, G; Sampson, J; Friedman, A; Friedman, H
Published in: Neuro-Oncology
November 1, 2014

Duke Scholars

Published In

Neuro-Oncology

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 1, 2014

Volume

16

Issue

suppl 5

Start / End Page

v12 / v13

Publisher

Oxford University Press (OUP)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Herndon, J., McSherry, F., Ravelo, A., Lipp, E., Healy, P., … Friedman, H. (2014). AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV). Neuro-Oncology, 16(suppl 5), v12–v13. https://doi.org/10.1093/neuonc/nou237.20
Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, K. Peters, et al. “AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).” Neuro-Oncology 16, no. suppl 5 (November 1, 2014): v12–13. https://doi.org/10.1093/neuonc/nou237.20.
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, et al. AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV). Neuro-Oncology. 2014 Nov 1;16(suppl 5):v12–3.
Desjardins, A., et al. “AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).” Neuro-Oncology, vol. 16, no. suppl 5, Oxford University Press (OUP), Nov. 2014, pp. v12–13. Crossref, doi:10.1093/neuonc/nou237.20.
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV). Neuro-Oncology. Oxford University Press (OUP); 2014 Nov 1;16(suppl 5):v12–v13.
Journal cover image

Published In

Neuro-Oncology

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 1, 2014

Volume

16

Issue

suppl 5

Start / End Page

v12 / v13

Publisher

Oxford University Press (OUP)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences